{"name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","slug":"juno-therapeutics-inc-a-bristol-myers-squibb-company","ticker":"","exchange":"","domain":"junoabristolmyerssquibbcompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BMS-986393","genericName":"BMS-986393","slug":"bms-986393","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_3"},{"name":"CC-97540","genericName":"CC-97540","slug":"cc-97540","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"Liso-cel","genericName":"Liso-cel","slug":"liso-cel","indication":"Relapsed or refractory large B-cell lymphoma","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BMS-986353","genericName":"BMS-986353","slug":"bms-986353","indication":"Hematologic malignancies (specific indication in Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"BMS-986393","genericName":"BMS-986393","slug":"bms-986393","phase":"phase_3","mechanism":"BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma","Relapsed or refractory chronic lymphocytic leukemia"],"catalyst":""},{"name":"CC-97540","genericName":"CC-97540","slug":"cc-97540","phase":"phase_2","mechanism":"CC-97540 is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"BMS-986353","genericName":"BMS-986353","slug":"bms-986353","phase":"phase_3","mechanism":"BMS-986353 is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","indications":["Hematologic malignancies (specific indication in Phase 3 development)"],"catalyst":""},{"name":"Liso-cel","genericName":"Liso-cel","slug":"liso-cel","phase":"phase_3","mechanism":"Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19.","indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory chronic lymphocytic leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQdkRLWXBta20xWmdOcnBiWE1tYXQyV1hOSUtSZC0wUHlyRm1aLTZ6YXI3Y2g0R3hxYnJKQThFSG8yNW5fUmpMV005VHZhRkFQY0JZTE1mRUQ1QnVjNzZvZml3OWgxRmxJUE9uY29TelltSmZoSHpfdDNDMkhpVGNsOVJ6YnJyZGRHa1BWMzh4X1lhTm9BdmVIYjZSaE1RWkg5N2FHbTl2QzdScUp4SU9FVHQ2VlNDV1IwYS1lMThnak4wVndJanFDanlOS3dxQQ?oc=5","date":"2025-12-05","type":"regulatory","source":"European Pharmaceutical Review","summary":"Bristol Myers Squibb wins fifth US approval for CAR T cell therapy Breyanzi - European Pharmaceutical Review","headline":"Bristol Myers Squibb wins fifth US approval for CAR T cell therapy Breyanzi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOXzNKeWNCOHRCX3NydHZUVnNwY0Jtcnp5bGY1Zk1hUVJFMkVlbGkzNktjZ0c0NDFjMDZzWHJVQ3BrUjd2a2pnRk9jYkVhd0M1NEJYRTh2SThtZFJINWlrT052aGU3aXV3Z3owbThhd0t0b1dUYW5LYUVJYk1lb01oY2VJQkc1bEpPbXNlQ1E0S0dvNTlxcjZtbFliT1Z3N2VQSGEweQ?oc=5","date":"2025-10-10","type":"deal","source":"Fierce Biotech","summary":"BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence - Fierce Biotech","headline":"BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9LNXNoUzRvQ2lnVVNzcTFIcHlkeHpXbGpZandrSW5UODhjb0ZjS0lLSVVXOUJ4OGJWT2ZleEtacTF2YUFTcDFnR0dYUXVaNVNxVERaNHliMWEtMnBKbVFJU29uOHB3OG5IVTNvTmFjQjl1WXZvN1h0c2FpUHl5QUk?oc=5","date":"2025-09-23","type":"pipeline","source":"Global Growth Insights","summary":"Who Are the Global Leaders in CAR T-Cell Therapy? Top 10 Companies List - Global Growth Insights","headline":"Who Are the Global Leaders in CAR T-Cell Therapy? Top 10 Companies List","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZm9DQVp0Q2s0b3VnenBmTVhOTm8xLWRmWVotUlRvSWhqc2Z4Y0dKMXVYVFJtc3pOci03VDVtN1M2aFRQUnhpdnA5NlFJVmUxVWRhb0h4bGRpOGF5VFoxaFZqVi10NEZHZ1Vsdjc0SXVHYXpxMUR0Q1NxWFJEc21SLUYyOU1uSGtNUnpfV3Jzck1wb3lRZUJkR0h5S3NFYUZ3ejJFOUNUOTFWNkVyakhTbw?oc=5","date":"2025-05-28","type":"deal","source":"PharmaTimes","summary":"TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform - PharmaTimes","headline":"TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNMDl5YUY1MUdEcWZReHZlVzh5ZGxoQS1xeFp1eDBVYkZSNUU3X1JFbDhzakZ6dFAxdndRMlVlUnBxVEdtYnVqX1pTZzBUV2ZaWnBsdWRRcDIwYXNYaVg2LXhYbFgtVXI0eEwyODh2U1ViVXpfV1RIU1pCdEduV1d5QzNoUnlXMmpMekgxdEI5Zks2dw?oc=5","date":"2025-05-28","type":"deal","source":"Contract Pharma","summary":"TQ Therapeutics Acquires Juno Therapeutics - Contract Pharma","headline":"TQ Therapeutics Acquires Juno Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQdTh3UU84Z1JGUm0wRDhDZWRnVXlKczY4UjNYN09VNUJuZHV0eDlkWmFwdGFCUkw5aDAzNlZXc2F2Yk5BTTZSV25lQ2JMcXZ5dDVTanBFb2JSaklTZHNFX0x1OUxZQm5FYjRnalh0T01mYW9mRmI3ZFA2d0luZ3VYa3pCSGhWWDhCX0E4?oc=5","date":"2025-02-05","type":"deal","source":"BioWorld News","summary":"Few biopharma mega-mergers hit the jackpot - BioWorld News","headline":"Few biopharma mega-mergers hit the jackpot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOa0NGUlRXR3FZS0lZOWFFbHV2RXk2R0NzeEstQ3hWRFNOZEdJVXRCM2lDSW9URnEtZld2ZkI4UHlJYmZSdWU5bUk0Q05ma1h2dkZiUGdITWlkWjVjLU5HR1BLa05jNnNSQmYzNm1qdTIyajNSVlRabnlTazFYV1JEekh5M2pjakMxRlBjM2R5WTFSU2IzbE1J?oc=5","date":"2023-01-09","type":"pipeline","source":"Fierce Pharma","summary":"Bristol Myers Squibb, Pfizer turned away from SCOTUS in high-profile cases - Fierce Pharma","headline":"Bristol Myers Squibb, Pfizer turned away from SCOTUS in high-profile cases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNYmhQVXhJN2gyX0pjRzhMM0xoZXNQTThfdkEwQUdYcWk5QWt1MmhCQUtQNi1va2FmN0pZUEl3Rk4wbjVjcFdoU2pXem10cjQ4dm9xYU1hZlBVbXFtdWpSRFJHWm1QQjgybHBUVV85SzI5dFFzdmpFTGktZmQ4MklQQUZ6NG1sOXhtNHpxU2R4WXZyVGRSck5sQ25HN2pqX09xNTNzd00zWG5fVG1FRzFNT1ZUcXlmdU1W?oc=5","date":"2022-11-07","type":"patent","source":"Reuters","summary":"U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead - Reuters","headline":"U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBEcjE0RllYMk9KQVJrbXpHeWZILXJfRzh2WUlwLVNadzhHeDA5ek1mYmVDV1J0M1REeFd3VGtHbEhxNE15UlVCekFNNS1oRlBXNEpvZXp6OXc0bEtfcTVlaXBIUmpUSnIwN19wMw?oc=5","date":"2021-06-17","type":"trial","source":"Wiley Online Library","summary":"TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL - Wiley Online Library","headline":"TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNVVR3cFp2Zm95dGhSUk0td3lVS05pLWU1UDlFeFhyZnBpaVQxZnVLTUwzeTljNFlmaXE0X3RsNWRWWDRXbnJxY0pZNVZ4aVEwMnN3YWVhSTRPR3E2d1NQZFFzOTdwTlBMczZTRFVsS3Z4aUEwajlMNl9jU3B0Wk1KalZJczNNSXJJY3c?oc=5","date":"2021-01-04","type":"pipeline","source":"BioPharma Dive","summary":"How an all-or-nothing bet on 3 Bristol Myers drugs came undone - BioPharma Dive","headline":"How an all-or-nothing bet on 3 Bristol Myers drugs came undone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPRWk2XzJBT1B1WlNuaXRoeWJHMWhZbDgzSUlnMnVBSnp6aUo4RlZGY0Z5ZHotUXlCLXpoZUx6dlRaNmlKRDNKdWlsVU4wdWxJUjVKSVRta2wyS0tkajFPTmRWM1FtN2tUSklYR1pvVHl0dlJoT2pmY1FQRjNEZFNjSU1hdU9JaVFSVHUzVDRGNFFRcm9ESFBwaQ?oc=5","date":"2019-12-04","type":"pipeline","source":"DCAT Value Chain Insights","summary":"The $74-Billion Marriage of Bristol-Myers Squibb and Celgene - DCAT Value Chain Insights","headline":"The $74-Billion Marriage of Bristol-Myers Squibb and Celgene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNMzZBQ0pnSTZEMzdvSTVnbUJ4djlkS29kOVJKbm5GN2d6MFJMc2VpYXFNODUtekJFTkpaTWxGTVU2WUNvN0FJTVR3Y21lM28yVklOR1FpVFRxMWVSRnJwQS1ha0FndUwycFRrd1NpVDAyZ21HSmgyS2Z4cXQwNnBZd05rSU0tYkMxN1NweEVRZ21Xa2RMd1UzOGZWQmp4ZmVnVjdJSlBWTVJ5ang0d0hLWUQ3WHk0NmNHZGVVM1BB?oc=5","date":"2019-01-10","type":"pipeline","source":"GeekWire","summary":"Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire","headline":"Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}